Analysts See $-0.95 EPS for Aclaris Therapeutics, Inc. (ACRS)

July 14, 2018 - By Jeanette Kaplan

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Logo

Analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report $-0.95 EPS on August, 14.They anticipate $0.39 EPS change or 69.64 % from last quarter’s $-0.56 EPS. After having $-0.98 EPS previously, Aclaris Therapeutics, Inc.’s analysts see -3.06 % EPS growth. The stock increased 0.78% or $0.16 during the last trading session, reaching $20.59. About 153,757 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 24.32% since July 14, 2017 and is downtrending. It has underperformed by 36.89% the S&P500.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $636.36 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

More notable recent Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news were published by: Nasdaq.com which released: “Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in …” on June 28, 2018, also Seekingalpha.com with their article: “Aclaris Therapeutics expands leadership team” published on June 15, 2018, Benzinga.com published: “The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus” on June 30, 2018. More interesting news about Aclaris Therapeutics, Inc. (NASDAQ:ACRS) were released by: Nasdaq.com and their article: “Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” published on July 03, 2018 as well as Nasdaq.com‘s news article titled: “Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients …” with publication date: June 26, 2018.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: